



June 4, 2024

Dear Member,

As you may recall, last fall we established a second Merck program (Merck Associates/Vaxneuvance) for practices that elected to use Merck's Vaxneuvance as their pneumococcal vaccine (vs Prevnar 20). We did this with the expectation that the extended grace period we were able to secure for members in our Standard Merck program requiring the use of Vaxneuvance would end.

That time has come - effective July 1st our Standard Merck program will no longer offer contract price discounts for Gardasil, Pneumovax, and Vaxneuvance but will maintain the same discounts for all other Merck products, including Rotateq, Varivax, MMR, Proquad, PedVaxHIB, and pediatric and adult Hepatitis A and B. If you need additional information about Vaxneuvance please visit: <https://www.merckvaccines.com/vaxneuvance-pediatric/>

Currently your practice is enrolled in our Standard Merck program (or you are part of a practice group that has locations enrolled in our Standard program). You are eligible to switch to our Merck Associates/Vaxneuvance program as follows:

- Contact us if: You are a **Pediatric Practice/Clinic AND** elect to use Vaxneuvance (by July) instead of Prevnar 20 for your infants.
- Contact us if: You are a **Family or Primary Care Practice/Clinic AND** elect to use Vaxneuvance (by July) instead of Prevnar for pediatric AND adult patients.
- Contact us if: You are an **Adult Medicine Practice/Clinic AND** are using or elect to use Vaxneuvance (by July) instead of Prevnar for your adult patients.
- **Women's Health Care Practices** will automatically be moved to our Merck Associates/Vaxneuvance program – no action is required.

If you would like to discuss and/or enroll in the Merck Associates/Vaxneuvance program, please notify us by email at info@atlantichhealthpartners.com or call us at 800-741-2044. It takes about three weeks to move a practice to the Merck Associates/Vaxneuvance program, and this can be done at any time in the future. The earliest effective date for any moves will be July 3rd.

We have shared with Merck that Family Practice and Primary Care groups may be disadvantaged with the requirement to only use Vaxneuvance in order to maintain the Gardasil discount. It is our understanding that Merck will likely launch an adult PCV vaccine sometime this year that may offer these practices a better option than the one outlined in this communication.

Attached is the Merck Price List effective July 1st for members of both programs.

As always, please contact us if you need any additional information.

Sincerely,

A handwritten signature in blue ink, appearing to read "Jeff Winokur".

Jeff Winokur, President
Atlantic Health Partners
Find us on Facebook, Follow us on LinkedIn